Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of
various types of malignant diseases. Mechanisms of PTX action represent several ways in …

Y‐box binding protein‐1 (YBX 1), a multifunctional oncoprotein containing an evolutionarily
conserved cold shock domain, dysregulates a wide range of genes involved in cell …

Approximately 75% of all breast cancers express the oestrogen and/or progesterone
receptors. Endocrine therapy is usually effective in these hormone-receptor-positive …

Acquired resistance to chemotherapy is a major obstacle in breast cancer (BC) treatment.
Accumulated evidence has uncovered that microRNAs (miRNAs) are vital regulators of …

Simple Summary Medulloblastoma is the most common malignant childhood brain tumour.
Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal …

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized
by metastasis, drug resistance and high rates of recurrence. With a lack or targeted …

Abstract Y-box binding protein-1 (YB-1), an important transcription and translation regulator
protein, is known to increase cancer cell invasiveness and spreading. Here, we report its …

Signaling via extracellular regulated kinase 1/2 (ERK1/2) and p90 ribosomal S6 kinase
(RSK), a downstream effector, mediates numerous processes. For example, ERK1/2-RSK …

Although hepatocellular carcinoma (HCC) is usually response to radiation therapy,
radioresistance is still the major obstacle that limits the efficacy of radiotherapy for HCC …

Nuclear expression of Y-box–binding protein (YBX1) is closely correlated with clinical poor
outcomes and drug resistance in breast cancer. Nuclear translocation of YBX1 is facilitated …